Hepion Pharmaceuticals Inc. (NASDAQ: HEPA)
$1.07
+0.0500 ( +4.90% ) 13.7K
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Market Data
Open
$1.07
Previous close
$1.02
Volume
13.7K
Market cap
$5.91M
Day range
$1.01 - $1.08
52 week range
$0.90 - $10.23
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-k/a | Quarterly Reports | 18 | Jun 25, 2024 |
10-q | Quarterly Reports | 76 | May 21, 2024 |
nt | Quarterly Reports | 1 | May 15, 2024 |
10-k | Annual reports | 87 | Apr 16, 2024 |
nt | Quarterly Reports | 1 | Apr 01, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
8-k | 8K-related | 14 | Mar 06, 2024 |
3 | Insider transactions | 1 | Mar 06, 2024 |
4 | Insider transactions | 1 | Feb 21, 2024 |
4 | Insider transactions | 1 | Feb 21, 2024 |